Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study

BACKGROUND: The current second-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma remains unsatisfactory. Anti-PD-1 monoclonal antibody combined with anti-angiogenic therapy shows anti-tumor activity and synergistic effect. We aimed to assess the efficacy and safety of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Jing, Chao, Wang, Junyun, Zhu, Mingyue, Bai, Zhigang, Zhao, Baoyi, Zhang, Jun, Yin, Jie, Yang, Xiaobao, Liu, Zongzhi, Zhang, Zhongtao, Deng, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932366/
https://www.ncbi.nlm.nih.gov/pubmed/35304622
http://dx.doi.org/10.1007/s00262-022-03174-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932366/
https://www.ncbi.nlm.nih.gov/pubmed/35304622
http://dx.doi.org/10.1007/s00262-022-03174-9

Ejemplares similares